Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women

dc.contributor.authorBonduki, Claudio Emilio [UNIFESP]
dc.contributor.authorLourenço, Dayse Maria [UNIFESP]
dc.contributor.authorBaracat, Edmund Chada [UNIFESP]
dc.contributor.authorHaidar, Mauro Abi [UNIFESP]
dc.contributor.authorNoguti, Maria Aparecida Eiko [UNIFESP]
dc.contributor.authorMotta, Eduardo Leme Alves da [UNIFESP]
dc.contributor.authorLima, Geraldo Rodrigues de [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T12:30:33Z
dc.date.available2016-01-24T12:30:33Z
dc.date.issued1998-03-01
dc.description.abstractBackground. This study was performed to evaluate antithrombin III levels in postmenopausal women receiving hormonal replacement treatment.Methods. It is a prospective randomized study concerning 19 postmenopausal patients, aged 40 to 65 years, who received either continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10) or daily transdermal 17 beta-estradiol 50 mu g (group B, N=9). Medroxyprogesterone acetate (5 mg/day, 14 days monthly) was given to all patients. Blood samples were obtained before and after 3, 6, 9 and 12 months of treatment. Coagulation tests included Antithrombin III (functional method), prothrombin time, partial activated prothrombin time, thrombin time, factor V, fibrinogen, platelet count and euglobulin lysis time. Friedman analysis of variance and Mann-Whitney test were used for statistical analysis.Results. Antithrombin III level was reduced (p<0.05) in group A but not in group B, although it remained within normal range. No changes were detected in the other coagulation tests.Conclusions. These data suggest that oral conjugated estrogen replacement reduces functional ATIII, whereas transdermal estradiol replacement therapy does not modify it.en
dc.description.affiliationUniversidade Federal de São Paulo, Div Endocrinol Gynecol & Climacterium, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Div Hematol, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Endocrinol Gynecol & Climacterium, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Div Hematol, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent330-333
dc.identifierhttps://dx.doi.org/10.1034/j.1600-0412.1998.770315.x
dc.identifier.citationActa Obstetricia Et Gynecologica Scandinavica. Copenhagen: Munksgaard Int Publ Ltd, v. 77, n. 3, p. 330-333, 1998.
dc.identifier.doi10.1034/j.1600-0412.1998.770315.x
dc.identifier.issn0001-6349
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/25876
dc.identifier.wosWOS:000072713400015
dc.language.isoeng
dc.publisherMunksgaard Int Publ Ltd
dc.relation.ispartofActa Obstetricia Et Gynecologica Scandinavica
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAntithrombin IIIen
dc.subjectEstrogenen
dc.subjectHormonal replacementen
dc.subjectMenopauseen
dc.subjectThromboembolismen
dc.titleEffect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal womenen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções